The other day I talked to our daughter, Janice, about my
reading of the development of monoclonal antibody (from historical perspective)
and its impact on current clinical medicine.
She alerted me the CRISPR, which is basically a gene editing.
There are two components of gene editing: One is Cas9 enzyme
which cuts DNA and the other is a snippet of RNA that guides the molecular
scissor to where the researcher wants to cut, using the complementary DNA-RNA sequences. As the RNA sequences can be custom made, so
the scientists can cut the DNA as he/she pleases.
While reading gene editing, my mind went right to sickle
cell anemia. In
1957 (at Cambridge U Cavendish Lab, supported by Max Perutz and Francis Crick)
Vernon Ingram discovered the replacement of Glutamic acid by Valine at 6th
position of β-globin chain of sickle cell HbS as predicted by Linus Pauling.
In an article published in Science (11/25/1949), Linus Pauling
demonstrated the hemoglobin from ones with sickle cell anemia has a different electrophoretic
mobility from that of a healthy individual.
Pauling’s quick mind led him to suggest that the difference was the
result of different ionizable amino acids sequence.
Pauling was indeed correct. A replacement of a single amino acids in
hemoglobin can wreak such havoc. The life
as we know it is so precise. This is why
medicine has to be exact and precise that science calls for.
This is how sickle cell anemia was
the first disease confirmed to be the molecular disease. Vernon Ingram (born in Germany, left for
England, repulsed by Hitler Nazi, spent some years in Rockefeller Institute and
Yale U.) was touted as the father of molecular medicine; I would call Pauling
the grandfather of molecular medicine.
I initially got excited that gene
editing would be the ideal way to “cure” sickle cell anemia by re-replacing the
Glutamine back to the position 6 of β-globin chain. Then I read the news of a gene-editing
(CRISPR) summit in December 2015, convened by U.S. National Academies of
Sciences and Medicine, Chinese Academy of Science and Royal Society of London. The summit statement calls for cautious development
of medical applications such as correction of the mutation that cause sickle
cell anemia or modification of immune cells to target cancer.
This is almost tantamount to a moratorium to ban the gene
editing research. You may be interested in
reading the story of “Sidney Brenner and the lift of the ban on recombinant DNA
research” that I posted in 2011. Brenner
is about 90 now, this may stir this “lion in winter” again.
It is still difficult to predict the use of gene editing in
clinical medicine, not only when, but also “if” (can be used). Scientific progress is inexorable; the
research must go on, although caution indeed has to be exercised as we’re
tinkering with the “Language of God”.
CRISP (clustered regularly interspaced short palindromic repeats) is a prokaryotic immune system, a way how bacteria
acquire “acquired immunity”. Cas9 was the
first nuclease discovered. The scientists got the idea of gene editing by
studying how bacteria work to confer resistance to foreign genetic elements.
















